Home > Rheumatology > EULAR 2022 > Late-Breaking Oral Abstracts > Baricitinib could open the door to oral treatment for juvenile idiopathic arthritis

Baricitinib could open the door to oral treatment for juvenile idiopathic arthritis

Presented By
Prof. Athimalaipet Ramanan , Bristol Medical School, United Kingdom
Conference
EULAR 2022
Trial
Phase 3, JUVE-BASIS
Doi
https://doi.org/10.55788/7d40a274
In a phase 3 withdrawal trial, the JAK 1/2 inhibitor baricitinib demonstrated great potential for flare prevention in juvenile idiopathic arthritis (JIA). Disease exacerbation was noted in 17% of participants on the study drug but in more than half of the placebo-treated participants. The term juvenile idiopathic arthritis subsumes various acquired immune-mediated diseases [1–3]. Currently, treatment options such as conventional synthetic or biologic disease-modifying antirheumatic drugs (csDMARD or bDMARD) are frequently used. “Our patients and parents have been waiting for oral alternatives to injectable drugs and the JAK inhibitors have come at the right time,” Prof. Athimalaipet Ramanan (Bristol Medical School, United Kingdom) expressed as he reported on the phase 3 JUVE-BASIS trial (NCT03773978) [1]. JUVE-BASIS assessed baricitinib in JIA with...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on